ADCT Overview

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.

Wall Street analysts forecast ADCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADCT is7.33 USD with a low forecast of 5.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

ADC Therapeutics SA revenue for the last quarter amounts to 18.06M USD, increased 6.79

ADC Therapeutics SA. EPS for the last quarter amounts to -0.04 USD, decreased -86.21

ADC Therapeutics SA (ADCT) has 263 emplpoyees as of March 12 2026.

Today ADCT has the market capitalization of 604.52M USD.